0,sarcoplasmic reticular
1,.97s
2,carbohydrates
3,active
4,inroads
5,deactivation
6,emergency
7,right grip
8,p38
9,atropine infusion
10,emergency room
11,left ventricular ejection time
12,anterior leaflet
13,donors
14,cellular
15,feasibility
16,median
17,splice
18,resting
19,acetyltransferase
20,regurgitation
21,left ventricular base
22,systolic ventricular function
23,arginine vasopressin
24,qt intervals
25,cardiac
26,caspase-3
27,walking
28,acute heart failure
29,force
30,ventricular systolic hf tissue
31,diminished
32,protocol-driven poc testing
33,sensitivity
34,degenerative mr
35,asymptomatic
36,wk
37,highly
38,glycolysis
39,pulmonary arterial hypertension
40,pulsatile
41,fibrillation
42,nontrastuzumab users
43,bet
44,time of inclusion
45,rv failure
46,histone
47,method
48,oht
49,genes
50,induced pluripotent stem cell-derived cardiomyocytes
51,depressed
52,left bundle-branch block
53,nonfunctional channels
54,lowest
55,severe-end-stage
56,acute care surgery
57,moderate-quality
58,axis function
59,transfusions
60,multivariable adjustment
61,low-volume
62,postoperative
63,national income per capita
64,redo sternotomy
65,levitated centrifugal-flow chronic
66,control
67,hemostasis
68,prevalence
69,admissions
70,se
71,acs
72,congestion-like
73,outcomes
74,reliable
75,inconsistent
76,breakdown
77,limbs
78,rate ratio
79,ischemic conditioning
80,mitochondrial-targeted antioxidant
81,effect
82,vagal tone
83,sex-specific models
84,relative
85,adenosine
86,statistically
87,overall
88,prolongation
89,morphologically
90,soluble
91,bottleneck stent
92,advanced
93,left atrial area
94,myofibre
95,knockdown
96,canine
97,vascular stiffness
98,revision
99,structured telephone support
100,injections
101,ami
102,stabilize
103,single-payer
104,correlates
105,ng
106,credible interval
107,mitochondrial
108,multivariable logistic analysis
109,mutant
110,antiadrenergic
111,myocardial insulin resistance
112,acute right heart failure
113,multicenter trial
114,demographic
115,single-cohort study
116,dyssynchrony
117,clustering
118,propensity score
119,aldosterone blockade
120,(egfr)-group
121,acute hf diagnosis
122,regression models
123,2 signalling
124,remote monitoring
125,anaesthesia
126,renin - angiotensin-aldosterone pathway
127,event-free
128,rheumatoid arthritis
129,concentric hypertrophy
130,aged 55
131,pay-for-performance
132,pathophysiology
133,ejection fraction
134,peripheral muscles
135,economic savings
136,aortic valve
137,peritoneal dialysis
138,atp
139,ratio
140,referral
141,pediatrics
142,terminal heart failure
143,hdl-mediated
144,neurohormonal stimulation
145,phase
146,cohort analysis
147,real-world
148,body mass
149,normalization
150,pacing-induced dilated cardiomyopathy
151,pyridostigmine
152,study-related
153,patients
154,tomographic angiography
155,electron microscopy
156,clinicians
157,mediterranean
158,hf
159,nonidentification
160,pulseless ventricular fibrillation
161,ischemia
162,subvalvular
163,chronic systolic heart failure
164,rate
165,pharmaceutically
166,complex
167,growth factor
168,myocyte differentiation
169,hfvt(+)
170,non-aa
171,cardiovascular surgeons
172,transmitral
173,uninephrectomy
174,caspase
175,pluripotency
176,hypothermic circulatory arrest
177,β-adrenoceptor blockade
178,n=11
179,left ventricular hypertrophy
180,gluconeogenesis
181,renin-angiotensin system
182,m2
183,in vitro
184,high-density lipoprotein
185,transplants
186,e / e'septal
187,phenotypes
188,borderline
189,untranslated
190,ischemic cardiomyopathy
191,upr
192,time-varying covariates
193,total cholesterol
194,diastolic mitral flow velocity
195,stroke volume
196,perturbations
197,rabbits
198,right heart failure
199,halt
200,overlapping
201,insulin-resistance
202,r=-0.12
203,retention
204,atherosclerosis
205,explant-derived cells
206,pulse
207,descriptive study
208,post
209,slowness
210,induction
211,arterial tonometry
212,bisoprolol
213,risk predictor
214,longitudinal
215,cardiogenic shock
216,prognostic
217,independently
218,renal dnx
219,apoptotic cells
220,epicatechin-rich cocoa
221,metabolic
222,myocardial ischemia
223,device
224,non-ischemic heart failure
225,catabolism
226,diseased
227,sonographic
228,osteoporosis
229,flow-mediated dilatation
230,post-translational state
231,β1ar
232,random-effects models
233,time-varying
234,egfr
235,training-induced
236,retrospective cohort study
237,anti-oxidant defence
238,value=0.033
239,diminishing
240,mortality
241,idiopathic dilated cardiomyopathy
242,mitochondrial-targeted peptide
243,reversal
244,radial arterial tonometry
245,histological
246,preoperative
247,renal
248,protocol
249,systolic volume index
250,post-tac
251,3m
252,evidence gaps
253,rm
254,heterogeneous
255,mechanisms
256,left ventricular systolic
257,dyslipidemia
258,hepatic function
259,telephone
260,multivariate
261,myofilament
262,vasodilator
263,decoy
264,recovery
265,beta-adrenergic
266,edge-to-edge
267,methotrexate
268,exercise duration
269,mid lad
270,confounders
271,signalling proteins
272,angiotensin-converting enzyme inhibitors
273,exercise capacity
274,peripheral artery disease
275,pollution
276,cardiac filling pressures
277,catheterization
278,prostate
279,coronary occlusion
280,cardiovascular function
281,fontan
282,effectiveness
283,unchanged
284,left ventricular
285,hypertension
286,benefit
287,single-center
288,off-pump
289,prevention
290,heart rate variability
291,low testosterone
292,neurohormones
293,nondiabetic
294,ahf
295,length of stay
296,circulatory assist device
297,acute β-ar
298,np
299,vasopeptidase inhibitors
300,results
301,micrornas
302,substantial
303,spontaneous vt
304,flow velocity
305,6-minute walking distance
306,antiarrhythmic
307,system
308,dyspnea
309,or
310,sst2 titrated
311,urban
312,perceived barriers
313,body mass ratio
314,hypoxia
315,long-term support
316,beta receptor blockers
317,end-of-life
318,evolving
319,peptide
320,extubated
321,peak respiratory quotient
322,(31)p
323,stable heart failure
324,post-dash
325,medicare
326,paediatric
327,age-
328,cardiopulmonary exercise testing
329,ankle-brachial index
330,preserved left ventricular ejection fraction
331,exercise testing
332,6mwt
333,biologic
334,peripheral muscle pump
335,chronic heart failure
336,validation
337,care delivery
338,quick
339,prescription
340,extracorporeal membrane oxygenation
341,network
342,methylatropine
343,sarcomeric microstructure
344,duration
345,stroke volume index
346,hazard ratio
347,re-hospitalization
348,terminologies
349,proportional hazards models
350,polymorphisms
351,pressure volume relation
352,antirheumatic drug
353,right ventricular dysfunction
354,downward
355,benign
356,phosphorylation
357,practice
358,interaction
359,left ventricular diastolic function
360,medication
361,flow reserve
362,mixed-methods study
363,β-adrenergic receptor
364,pioglitazone
365,cytochrome c
366,polymerase
367,operations
368,organic
369,rs1799945
370,noncardiac
371,embolism
372,reduced
373,blots
374,coronary interventions
375,v.6.2
376,fat mass index
377,cornerstone
378,factorial
379,mitochondrial respiration
380,leg
381,gastrointestinal
382,burden
383,variance
384,heart-specific
385,better-than-usual
386,exchange
387,elevations
388,overlapped
389,content-driven telehealth
390,kinases
391,antagonizing
392,mitochondrial oxidative phosphorylation capacity
393,diuretics
394,af-free
395,right atrial
396,panel
397,toxicity
398,randomized
399,pacemaker
400,channel
401,acute ischemic right heart failure
402,basal contractility
403,responsiveness
404,n=9
405,differential analysis
406,explanted
407,attenuated
408,clinics
409,perioperative
410,point of care
411,fit
412,bisphosphonates
413,myocardial infarction-both
414,implants
415,epifluorescence microscopy
416,enhancement imaging
417,severely
418,walk test distance
419,sympathetic nervous systems
420,epithelial
421,chronic kidney disease
422,implantable cardioverter-defibrillator device
423,right ventricular function
424,further examination
425,intricately
426,large-scale
427,diastolic mitral
428,physician
429,disease complex
430,pace
431,plasticity
432,transverse aortic constriction
433,right
434,transcription factor
435,imaging
436,pro-b-type
437,likelihood ratio
438,sudden
439,significantly
440,aged ≥18
441,two-vessel
442,commissioning
443,quantification
444,insulin-signaling
445,6-minute walked distance
446,decompensated systolic heart failure
447,noncardiovascular
448,6-wk
449,denervation
450,controlled feasibility study
451,lvet
452,endothelial no synthase activation
453,multivariable models
454,donor
455,/ 2100 kcal
456,atrial natriuretic peptide
457,myosin
458,bottleneck stenting
459,healthy
460,infusions
461,systolic function
462,rehabilitation
463,regional strain
464,glucocorticoids
465,pulmonary arterial pressure
466,exerted
467,dt
468,atrioventricular delay
469,inhibitors
470,x12
471,projections
472,all-cause hospitalizations
473,composite end-point
474,profound
475,open chest model
476,pg
477,sympathetic
478,debilitating
479,withdrawal
480,misdiagnosis
481,non-invasively
482,moderate
483,thigh
484,nonischemic cardiomyopathies
485,nontreatment
486,aged
487,perceived
488,human embryonic kidney
489,myocardium
490,australian
491,etidronate -
492,conservation
493,early-onset hf
494,guideline-mandated
495,basal
496,assist device
497,phenotype
498,n=36
499,bromodomain proteins
500,porcine
501,extended
502,s'lateral
503,inducible
504,high-risk
505,transmitral blood flow velocity
506,optimal
507,phospholipase
508,haplotype
509,blockade
510,susceptibility
511,throughput
512,eccentric
513,crf
514,prospective
515,hospitals
516,heart dilatation
517,vascular endothelial growth factor
518,end-diastolic volume index
519,early-onset
520,length-force relationship
521,risk-adjusted
522,malignancies
523,sham-inv
524,unstable
525,high-cost
526,inverse correlation
527,n=431
528,centers
529,central venous pressure
530,effective rate control
531,out-patient
532,intravenous iron
533,(-)-erc
534,filling pressures
535,idiopathic-dilated cardiomyopathy
536,gut
537,chronic organ failure
538,cardiac support
539,ring annuloplasty
540,double-blind
541,per capita
542,parasympathetic neurotransmission
543,lying
544,severe
545,neprilysin blocks
546,adverse event
547,acute dyspnea
548,erasers
549,systolic pressure
550,vasodilators
551,nordic
552,transoesophageal echocardiographic
553,pulmonary hypertension
554,emotional status
555,parasympathetic control
556,transforming
557,nps
558,isoprenaline
559,effectors
560,point
561,ameliorated
562,myocardial function
563,explant-derived progenitor cells
564,mass index
565,catabolic
566,adipokines
567,late-activated
568,randomised-controlled trials
569,operation
570,glucocorticoid
571,polymorphism
572,demographics
573,eo-cfus
574,sandwich
575,n=197
576,angina
577,transmitral flow velocities
578,inpatient
579,infusion
580,interaction terms
581,inverse
582,periprocedural
583,immunohistochemistry
584,cardiac tissues
585,cardiologist
586,tachycardic
587,salt loading
588,progenitor cells
589,intraclass correlation coefficient
590,pulse-wave velocity
591,ethnic groups
592,polytetrafluoroethylene tube
593,pathophysiologic
594,elevation
595,myocardial angiogenesis
596,myocyte depolarization
597,regression line
598,reoperation
599,abdominal
600,neurohormone
601,arrhythmia
602,strongly
603,normal albumin concentration
604,obese
605,signaling pathway
606,electrocardiographic
607,disease-specific
608,hypertensive hfpef
609,actin cytoskeleton pathways
610,setting
611,peripheral edema
612,n=71
613,cardiac progenitor function
614,rv
615,followed up
616,randomly
617,dopamine
618,fat-free mass index
619,currents
620,intravenous metoprolol
621,truncated
622,left bundle branch block
623,circulatory support
624,applicable
625,cost-effectiveness
626,lb
627,beta-blockers
628,exercise time
629,expression
630,chromatin subproteome
631,diastolic mitral annular velocity
632,biomarker
633,transcription
634,medically
635,twist
636,thirty-seven
637,reclassified
638,cation channel
639,right atrium
640,ref
641,hospital
642,radial strain
643,observational study
644,right coronary artery
645,ventricular diastolic function
646,postischemic heart failure
647,isoenzymes
648,rhythm-control
649,rate-control
650,nonglycosylated
651,participatory
652,pulmonary arterial systolic pressure
653,coronary arteries
654,link
655,study
656,anthracycline metabolism
657,at-risk
658,ventricles
659,clinically
660,joint effect
661,ie
662,n=44 925
663,prescriptive
664,diagnoses
665,ras -
666,pulmonary disease
667,adiponectin
668,occlusion
669,trastuzumb-related
670,transcription factors
671,diastolic filling time
672,diabetes mellitus
673,degenerative mitral regurgitation
674,blacks
675,eplerenone
676,performed
677,readily
678,embryonic
679,t1 / 2
680,end-systolic elastance
681,cardiac event
682,hm
683,platelet-activating factor
684,percutaneous
685,parallel-group
686,risk factors
687,exhaustion
688,systematic review
689,total arterial compliance
690,meta-analyses
691,hemodynamic
692,hyponatremia
693,systematic
694,vad
695,well-treated
696,intubated
697,mixed linear models
698,contractile response
699,cardiac arrest
700,xo
701,2 receptors
702,molecular scaffolds
703,validity
704,aerobic exercise
705,ischemic
706,invasive haemodynamic
707,pulsatile devices
708,stem cell
709,angiotensin-receptor neprilysin inhibitors
710,dyssynchronous heart failure
711,in
712,inhibition
713,transplant
714,neutral
715,interpretation
716,p=0.03
717,research design
718,ventricular tachycardia
719,mitochondrial oxidative stress
720,amplitude
721,prognostically
722,cardiomyopathy
723,so-called end stage
724,swine
725,assisted
726,calcium-sensitizing agents
727,natremia
728,rate control
729,cardiorespiratory fitness
730,peak vo2
731,identification
732,mitochondrial-targeted peptides
733,first-in-class inhibitor
734,positively
735,p=0.036
736,covariates
737,discharge
738,iron-deficient
739,fetal
740,kappa coefficients
741,cardiac index
742,mir-25
743,interrelated
744,survival
745,score-matched
746,chronically
747,cardiotoxicity
748,myocardial tissues
749,nursing
750,depressed left ventricular
751,lc-ms
752,non-dnx
753,nonprescribing
754,cardioversions
755,cardiovascular reserve
756,driven
757,hf-ref
758,exertion
759,stemming
760,s'septal
761,blood flow
762,modestly
763,right ventricular contractile function
764,heart disease
765,circumferential strain
766,expertise
767,mechanical cardiac support
768,high-dose
769,evidence
770,bradycardic
771,descriptive statistics
772,university
773,early
774,incidence
775,ranging
776,myocardial ischaemia
777,nanomolar
778,aim
779,citrate
780,activators
781,surrogate
782,rs10927887
783,self-identified
784,coronary heart disease
785,or preserved
786,symptoms
787,saf
788,euthanization
789,hf-action
790,lung
791,collaborative research initiatives
792,all-cause
793,apoptotic signaling pathway
794,myocytes
795,emotional stress
796,sarcopenic range muscle
797,cardiovascular diseases
798,acute kidney injury
799,dilated cardiomyopathy
800,volume overload
801,inotropic
802,therapeutic
803,diastolic function
804,liver-specific
805,beta-dependent
806,diastolic dysfunction
807,dementia
808,tachycardia
809,aetiologies
810,cardiac pathogenesis
811,stroke
812,gadolinium-chelate contrast agent
813,superior
814,catalytic
815,methodology
816,phosphocreatine
817,icu
818,progression
819,underlie
820,biventricular support
821,cpcs
822,serum cystatin c
823,atropine
824,high-fat
825,hypertrophy
826,ventricular tachycardia storm
827,grain
828,physiology
829,profoundly
830,downstream
831,global attenuation
832,delivery
833,regulatory subunit
834,ejection time
835,retrospective
836,self-care education
837,peripheral abnormalities
838,in vivo
839,fibrosis
840,angiogenesis
841,reference values
842,β2-receptor
843,confirmatory factor analysis
844,multiorgan failure
845,biomarker-guided
846,systemic vascular resistance
847,blood pressure control
848,atrial pacing
849,sd
850,exacerbation
851,right heart
852,bleeding
853,proteomics
854,catheter
855,assembly
856,nationwide
857,goal-directed
858,pro-adrenomedullin
859,right atrial mass
860,hhf
861,cardiac rehabilitation
862,antiplatelet agents
863,observational cohort studies
864,embedded
865,amino-terminal pro-b-type natriuretic peptide
866,severity
867,full-length
868,odds ratios
869,receptor
870,p70s6k
871,venous thromboembolism
872,left ventricular assist device
873,excursion
874,biological phenotype
875,patient-years
876,renal impairment
877,extensive
878,cardiovascular death
879,cardiac looping
880,magnetic resonance imaging
881,health-related
882,technology
883,rna
884,ischemic-hypertensive cardiomyiopathy
885,renal chloride channel
886,extracorporeal membrane oxygenation membrane support
887,posterior wall
888,systole
889,clinical
890,flow-mediated dilatation diameter
891,cost-minimization
892,electromechanical
893,circulating
894,dual-energy
895,load-corrected
896,mirnas
897,extracted
898,ecgs
899,pulmonary
900,tactics
901,cardiac amyloidosis
902,carotid
903,functional class
904,ambulatory
905,breath-holding
906,pharmacological
907,hscrp
908,spectrometry
909,left ventricular ejection fractions
910,mesenchymal transition
911,ventricular myocytes
912,hf with preserved ejection fraction
913,bridge
914,reversibility
915,oral
916,n=120
917,well-being
918,telehealth
919,β2-adrenergic receptor
920,mass
921,mammalian
922,perceived social support score
923,dialysis
924,wild-type
925,annular plane
926,k=252
927,modulated
928,intensive
929,stent coated
930,vasopressin
931,dd
932,cyclase
933,health care
934,participants
935,prescribe
936,coronary angiography
937,within-day test-retest
938,heart rate variation
939,united states
940,heart rate
941,irs2
942,mitral annulus velocities
943,aldosterone antagonism
944,molecular
945,diuretic
946,micronutrients
947,resting hemodynamics
948,anthracyclines
949,invasive
950,curative
951,intravenously
952,lesion
953,industrial
954,intake
955,trastuzumab-related
956,span
957,splicing
958,echo-doppler
959,cells
960,neprilysin inhibition
961,writer
962,pharmacologic
963,oxidation
964,all-cause readmissions
965,preserved
966,comanagement
967,biventricular dysfunction
968,respiratory gas analysis
969,metrics
970,maximum oxygen consumption
971,neurohormonal systems
972,regulator
973,lean mass quantification
974,sacubiltril - valsartan
975,coronary microembolization-induced hf
976,non-randomized
977,difference-in-differences
978,downstream signalling
979,cardiovascular outcomes
980,cross-linking
981,ventricular structure
982,postmenopausal
983,peak aerobic capacity
984,downregulated
985,actin cytoskeleton
986,pathological stress
987,lateral
988,radiological
989,uk
990,systolic parameters
991,quality of care
992,collagen
993,monophosphate
994,therapeutics
995,lvad
996,diastolic blood pressure
997,proximal
998,followed
999,variability
1000,pulmonary congestion
1001,fat
1002,midpapillary
1003,non-diastolic
1004,(123)i-meta-iodobenzylguanidine
1005,pressure-overload-induced
1006,late-onset hf
1007,frailty
1008,hospitalization
1009,weak grip
1010,divergent
1011,extracellular flux analyzer
1012,limited evidence
1013,randomised
1014,s '
1015,exogenous
1016,circumferential shortening
1017,support
1018,hazard
1019,subcellular
1020,median rate ratio
1021,anastomosis
1022,(123)i-mibg
1023,life-threatening
1024,valvular disease
1025,body
1026,ms
1027,reversible
1028,evidence-based
1029,rates
1030,breathing
1031,peak oxygen consumption
1032,left pulmonary artery
1033,driveline
1034,qualitative
1035,anthracycline
1036,empirically
1037,renin-angiotensin-aldosterone system
1038,lesions
1039,implications
1040,sequence
1041,n=1543
1042,coronary disease
1043,renin-angiotensin-aldosteron
1044,neurohormonal
1045,invasively
1046,autologous
1047,schfi
1048,electrocardiogram
1049,cancer
1050,parasympathetic activity
1051,pre-participation
1052,insulin
1053,systolic elastance
1054,altered
1055,thrombotic obstruction
1056,internal diameter
1057,protection
1058,carcinoma
1059,metabolic enzymes
1060,matched-pairs
1061,1a
1062,diseases
1063,senescence
1064,early-outgrowth colony-forming units
1065,composite endpoint
1066,unloading
1067,secondary end point
1068,tissue
1069,dobutamine
1070,aging
1071,early rhythm control therapy
1072,acute hf
1073,stand-alone
1074,infarction
1075,kidney index
1076,discrepancy
1077,electronic
1078,anemic
1079,signaling pathways
1080,interventricular septum
1081,air pollution
1082,myofibrillar ca
1083,renal disease
1084,age-by-lvef
1085,nutrition
1086,cytoskeletal actin
1087,central
1088,implanted monitoring devices
1089,metabolic exercise
1090,steady
1091,medical
1092,case-control analysis
1093,ejection fractions
1094,source
1095,pacemakers
1096,aucs
1097,unilateral
1098,stimulation
1099,catheterisation
1100,rationale
1101,valve plasty
1102,dna
1103,first-in-man
1104,contractile efficiency
1105,proteome
1106,anti-inflammatory
1107,usefulness
1108,ste
1109,dhand
1110,serum albumin
1111,catheter ablation
1112,titrated
1113,ivabradine
1114,infection
1115,antibodies
1116,moderate-severe
1117,environment
1118,valvular regurgitation
1119,treatment
1120,interleukin receptor
1121,drug-untreated
1122,inducing
1123,skeletal muscle
1124,correlate
1125,right-sided cardiac catheterization
1126,tnf antagonist
1127,flow
1128,telemonitoring
1129,dearth
1130,value=0.631
1131,primary end point
1132,tobacco
1133,gene expressions
1134,herbal
1135,frail
1136,fatty acids
1137,fee-for-service
1138,behavioural-change
1139,center retrospective observational study
1140,kinase-2
1141,biosynthetic enzymes
1142,beta-adrenergic receptor
1143,hazards models
1144,absence of changes
1145,dysfunction
1146,impact
1147,tonometric
1148,long-term
1149,heart mass
1150,ring
1151,heart iron
1152,hand-searching
1153,gender-matched control subjects
1154,free-breathing pulse
1155,myocyte-specific
1156,sympathovagal balance
1157,mitochondrial complex
1158,systolic heart failure
1159,clinician
1160,systematic review protocol
1161,oxidase inhibition
1162,pathogenesis
1163,sensitized
1164,nationally
1165,attrition
1166,exercise rehabilitation
1167,genomic
1168,risk stratification
1169,linear models
1170,r=0.67
1171,erc
1172,end point
1173,right ventricular support
1174,centrifugal flow pump
1175,all-cause readmission
1176,surgical
1177,stent
1178,uptitrations
1179,rhythm
1180,camp production
1181,nbdmards
1182,mechanism
1183,heart
1184,implanted
1185,exploratory factor analysis
1186,elevated
1187,anthracycline-containing
1188,testosterone
1189,upper
1190,10-cell
1191,deciles
1192,rate constant
1193,sst2
1194,left ventricular filling
1195,6-minute walk distance
1196,smoking
1197,sternal
1198,neoangiogenesis
1199,bivp
1200,inflammatory
1201,coronary artery
1202,isoforms
1203,co-primary outcome
1204,autonomic imbalance
1205,angiotensin-receptor blocker
1206,acute rv failure
1207,normal
1208,internists
1209,transcript
1210,left ventricular ejection fraction
1211,sarcomere shortening
1212,carvedilol
1213,autonomic dysbalance
1214,specificity
1215,ventricular
1216,competitive
1217,dilatation
1218,speckle tracking echocardiography
1219,temporal
1220,disease progression
1221,tachycardia-induced heart failure
1222,nuclear factor-κb
1223,reclassification
1224,explants
1225,neurohormonally
1226,care transfer
1227,metric
1228,vs
1229,center
1230,upregulated
1231,detergent
1232,replicate
1233,coprimary
1234,considerable
1235,blood pressure
1236,β-blockers
1237,dynamic
1238,social
1239,lusitropic
1240,clinic
1241,linear pathway
1242,acute anthracycline-induced cardiotoxicity
1243,aortic valve surgery
1244,2-fold
1245,descending artery
1246,pressure
1247,inactive
1248,12-s
1249,net-reclassification-improvement
1250,palliative
1251,reduced ejection
1252,small-molecule inhibitors
1253,implantable cardiac arrhythmia devices
1254,arterial pressure
1255,congenital
1256,r=-0.62
1257,descriptive
1258,feeding
1259,controlled
1260,quasi-experiment
1261,remarkable
1262,repolarization
1263,surgically
1264,parasympathetic
1265,hemodynamically
1266,diuretic response
1267,cardiac murmurs
1268,beta blockade
1269,coupling
1270,amyloidotic
1271,antiplatelet drugs
1272,mlhf
1273,rheumatic
1274,cardiomyocytes
1275,resistance training
1276,hdl-bound
1277,right ventricular pacing
1278,ml
1279,neuro-hormonal system
1280,hf with reduced ejection fraction
1281,multivariate analyses
1282,angiotensin converting enzyme inhibitor
1283,outcome
1284,annular plane systolic excursion
1285,cardiac deaths
1286,epidemic
1287,nonfatal
1288,co
1289,liver disease
1290,power
1291,protective peptides
1292,awful
1293,potassium
1294,propranolol
1295,independent
1296,interval
1297,sci
1298,gene expression
1299,thorough
1300,tension
1301,ivabradine-treated
1302,myocardial pde2
1303,ultrasonography
1304,cited
1305,metabolic pathways
1306,aortocaval fistula
1307,anaerobic metabolism
1308,study-a multicenter
1309,refractory
1310,heart rate response
1311,blood glucose
1312,fiber
1313,non-sudden
1314,p38α mitogen-activated protein kinase
1315,limitation
1316,parasympathetic function
1317,antagomir
1318,cessation
1319,hemocompatibility
1320,acp
1321,sustained
1322,ingenuity pathway
1323,prodrug
1324,glucose
1325,15-ml
1326,sepsis
1327,consensus
1328,conditions
1329,continuous wave doppler echocardiography
1330,structured exercise
1331,undiagnosed
1332,relative wall
1333,zsf1
1334,cross talk
1335,functional mitral stenosis
1336,readmissions
1337,diastolic filling formalism
1338,internal
1339,triangular resection
1340,synthesise
1341,right ventricular
1342,muscle-wasting syndrome
1343,pressure-overload
1344,tailored
1345,medical therapy
1346,pre-post
1347,transplant-ineligible
1348,correlation
1349,proangiogenic
1350,max
1351,sound mind
1352,hfpef
1353,inflammatory state
1354,chronic renal failure
1355,desensitization
1356,left-to-right
1357,genetic
1358,echocardiograms
1359,non-survivors
1360,replacement
1361,placebo
1362,international
1363,n=68
1364,regulatory
1365,additive
1366,multisystem disease
1367,cardiovascular
1368,8-fluo-camp
1369,abrogate
1370,rapid
1371,cytotoxic
1372,strong acid
1373,autopsy
1374,non-fatal
1375,end-stage renal disease
1376,consultations
1377,women
1378,risk stratification models
1379,icd
1380,food-frequency questionnaires
1381,growth factor-β
1382,time-domain
1383,infancy
1384,cost analysis
1385,significance
1386,nitric oxide donors
1387,conclusion
1388,combined end point
1389,spontaneous ventricular tachycardia
1390,heart pathology
1391,left ventricular mechanics
1392,collateral growth
1393,nurse
1394,post-pd
1395,coronary artery calcium
1396,acute coronary syndromes
1397,inability
1398,muscular
1399,dose-dependent
1400,chronic hf-ref
1401,conjoint education
1402,reverse remodeling
1403,apex
1404,pre-pd
1405,pre -
1406,tumor necrosis factor
1407,overexpressing
1408,transplantation
1409,assist practitioners
1410,systemic
1411,lean body mass
1412,atrial tachyarrhythmias
1413,placebo-controlled
1414,ci
1415,entry
1416,diseased cardiomyocytes
1417,expansion
1418,chemotherapy-induced
1419,"n=625,595"
1420,c-kit
1421,prespecified
1422,serum
1423,propensity
1424,brachial
1425,jugular venous pressure
1426,recruitment
1427,angiotensin receptors blockers
1428,energy substrate metabolism
1429,theory
1430,anecdotal
1431,protein expression
1432,cardioprotective signaling
1433,cardiopulmonary bypass
1434,myocardial
1435,risk factor
1436,ees
1437,antagonist
1438,preserved left ventricular
1439,electrical
1440,nodularity
1441,rotor
1442,trial registries
1443,atherosclerotic cad
1444,signal transduction
1445,noninvasive surrogates
1446,bhlh
1447,evidenced
1448,β-myosin heavy chain
1449,axis
1450,distressing
1451,aldosterone
1452,veterans
1453,cumulative hazard
1454,orientation
1455,chronic obstructive pulmonary disease
1456,mapped
1457,post-translational states
1458,camp
1459,serial
1460,incubated
1461,stretch rate
1462,gastrointestinal bleeding
1463,beneficial
1464,bisphophonates
1465,adenosine monophosphate
1466,extend
1467,long-term survival
1468,at
1469,β-ar
1470,suboptimal
1471,sympathetic activity
1472,atherosclerosis risk
1473,haemodynamic stress
1474,higher-than-expected
1475,intubation
1476,confidence
1477,biventricular pacing
1478,myocardial tissue
1479,add-on
1480,itself
1481,tachy -
1482,stimuli
1483,tta
1484,dxa
1485,delayed rhythm control
1486,myocardial glycolysis
1487,end stage
1488,indicative
1489,functional enrichment analysis
1490,fluctuations
1491,pump
1492,negative
1493,rhythm control therapy
1494,subunit expression
1495,follow-up
1496,baseline
1497,thromboembolic events
1498,cancers
1499,trend
1500,p=0.02
1501,metabolism
1502,aortic
1503,cardiac autonomic balance
1504,recurrent hf
1505,single-arm
1506,c-kit + cells
1507,acute right ventricular pressure overload
1508,branches
1509,non-linear
1510,cognitive
1511,β-ar responsiveness
1512,interatrial shunting
1513,intensive care unit
1514,walk test
1515,obesity
1516,cardiac magnetic resonance imaging
1517,pharmaceuticals
1518,lipid-lowering
1519,ventricular-arterial coupling
1520,vivo
1521,non-urbanized
1522,joint associations
1523,meta-analyzed
1524,aerobic training
1525,atrial explant-derived c-kit + cells
1526,comorbidity
1527,prognosis
1528,aha
1529,apical
1530,sodium-restricted
1531,modulation
1532,aldosterone antagonist
1533,hypothesis-generating
1534,invasive hemodynamic assessments
1535,cachexia
1536,levitated
1537,breathlessness
1538,urine
1539,blood
1540,delineated
1541,p=0·0001
1542,multisite
1543,synchrony
1544,augmented
1545,preserved left ventricular ejection fractions
1546,nonstandardized
1547,aac
1548,epidemiology
1549,stenosis
1550,myocardial ischemic events
1551,inoperable
1552,non-hf
1553,nitroxyl
1554,all-cause hospitalisations
1555,extracorporeal support
1556,dialysis-dependent
1557,univariable analysis
1558,acute decompensated hf
1559,post-acute
1560,ischemic hf pathogenesis
1561,shotgun
1562,morphological
1563,e / e '
1564,mitral filling flow
1565,age-dependent
1566,atrial
1567,noninvasive
1568,von willebrand factor
1569,care
1570,post-lvad
1571,quantified
1572,pulmonary artery
1573,cardiac risk
1574,nurses
1575,vagal
1576,double-knockout
1577,septal
1578,renal denervation
1579,mineralocorticoid receptor antagonists
1580,plasma catecholamines
1581,encoding
1582,acetylcholinesterase inhibitor
1583,expenditure
1584,replicating
1585,correction
1586,pathophysiologically
1587,adenine nucleotides
1588,critical
1589,destination therapy
1590,diastolic mitral valve tethering
1591,protein
1592,non-diabetic
1593,right ventricle overload
1594,phospholamban
1595,left ventricular midpapillary
1596,end of life
1597,revascularization
1598,post hoc analysis
1599,epigenetic
1600,dynamics
1601,chelation
1602,standard error of measurement
1603,precipitating factor
1604,sustainability
1605,body mass index strata
1606,correlated
1607,remodeling events
1608,preserved ejection fraction
1609,capability
1610,stable
1611,raloxifene
1612,chromatin hyperacetylation
1613,valid
1614,vasodilatory
1615,radioenzymatic -
1616,cardiac output
1617,humanized
1618,pathological
1619,diastolic
1620,21 beagle
1621,eccentric hypertrophy
1622,embase
1623,subclinical
1624,implantable cardioverter defibrillators
1625,filling pressure
1626,curve
1627,net reclassification improvement
1628,objective
1629,elastic
1630,pathology
1631,1.5-t
1632,variation
1633,safety end point
1634,scaffold proteins
1635,cascade
1636,fluid overload
1637,augment
1638,dystrophin-associated protein complex
1639,renal underperfusion
1640,enriched
1641,α-myosin heavy chain
1642,malondialdehyde
1643,ventricular action potential
1644,hypotension
1645,left heart twist
1646,electrocardiographers
1647,p=0·016
1648,longitudinal systolic strain
1649,molecular dysfunction
1650,ascertained
1651,quality-adjusted
1652,pneumonia
1653,aortic valve insufficiency
1654,right ventricular assist device
1655,stroke score
1656,radial artery tonometry
1657,haemodynamic
1658,cardiac death
1659,thalassaemia
1660,centre
1661,paucity
1662,right ventricular-pulmonary arterial coupling
1663,follow up
1664,decongestion
1665,persistent
1666,coefficient
1667,pulmonary arterial vasculature
1668,refractory cardiogenic shock
1669,hallmark
1670,acute β-adrenoceptor blockade
1671,positron emission tomography
1672,blood transfusions
1673,≥160 ms
1674,reliability
1675,conduction
1676,endothelial dysfunction
1677,diagnosed
1678,nitrite
1679,low-quality evidence
1680,chromatin-associated
1681,human
1682,prolapse
1683,ingenuity pathway analysis
1684,permeability
1685,sex-matched
1686,area under the curve
1687,infarction-related
1688,functional capacity
1689,transfusion
1690,echocardiographic
1691,oxygen
1692,mitral stenosis
1693,phosphomimic
1694,postcontrast
1695,hemolysis events
1696,muscle
1697,immunoreactive
1698,depression
1699,cardiac filling
1700,overweight
1701,aiming
1702,end
1703,infrastructure
1704,viscoelastic
1705,unfolded protein response
1706,peak early
1707,troponin
1708,right ventricular assist devices
1709,patient-level
1710,e '
1711,palliation
1712,pilot
1713,reduced ef
1714,stems
1715,noncardiologist
1716,neuronal stressors
1717,end-diastolic volume
1718,fat free mass
1719,mitral valve area
1720,modulates
1721,signed-rank tests
1722,chronic
1723,wave ratio
1724,rv dysfunction
1725,meta-analysis
1726,controlled trial
1727,electromechanical delay
1728,web of complicity
1729,solid
1730,blinded
1731,cardiac remodelling
1732,renin-angiotensin system blocker
1733,2+)-pump function
1734,resynchronization therapy
1735,cogeneration
1736,contractility
1737,norepinephrine
1738,cost-effectiveness ratios
1739,cardiopulmonary exercise test
1740,angiography
1741,albumin
1742,hand grip
1743,dl
1744,functional ms
1745,province of québec
1746,brain natriuretic peptide
1747,endpoints
1748,autonomic balance
1749,terminal
1750,cystatin
1751,preserved lvef
1752,venoarterial dilation
1753,catheter-based
1754,production
1755,therapies
1756,proteomic remodeling
1757,stiffness
1758,cardiac transplant
1759,excised
1760,remodelling
1761,rr intervals
1762,osprey
1763,outcome-monitoring
1764,rv function
1765,weak
1766,implantable cardioverter-defibrillator
1767,measurable
1768,physical
1769,etidronate
1770,drug-free
1771,allogeneic
1772,biomarkers
1773,conductance
1774,myocyte
1775,implantable cardiac defibrillator
1776,single-centre
1777,american
1778,retrospective studies
1779,psoriasis
1780,peak quadriceps force
1781,signalling
1782,absorption function
1783,genotype
1784,beta1-adrenergic receptor
1785,iron
1786,creatine
1787,left ventricle
1788,pressure ulcers
1789,mild mitral regurgitation
1790,likelihood
1791,transcriptional pause
1792,chronic pulmonary arterial hypertension
1793,electrical stimulation
1794,cell
1795,distribution
1796,nucleolin
1797,cardiac transplants
1798,cardioprotective
1799,cost-effective
1800,sinus rhythm
1801,hypertensive heart failure
1802,urgently
1803,mechanistically
1804,contractile function
1805,longitudinal strain
1806,urinary tract infection
1807,gene-targeted
1808,neurological
1809,hybrid
1810,cardiac cachexia
1811,liver
1812,dilated
1813,p70s6k-ser
1814,systolic hf
1815,attenuation
1816,left ventricular systolic dysfunction
1817,angiotensin receptor
1818,wasting
1819,epinephrine
1820,meq
1821,professionals
1822,mitochondrial oxidative metabolism
1823,intolerance
1824,coexist
1825,non-biological disease
1826,rehospitalization
1827,aortic blood flow
1828,bromodomain
1829,transthoracic echocardiography
1830,major
1831,emotional
1832,exercise with testosterone
1833,flutter
1834,tac
1835,blood-flow paths
1836,os
1837,confounding
1838,mitochondrial structure
1839,myocardial perfusion
1840,life expectancy
1841,magnetic resonance angiography
1842,immunoprecipitation
1843,psychometric
1844,cerebral
1845,hfpsi
1846,myocardial collagen
1847,proteomic
1848,zebrafish
1849,endopeptidase inhibitors
1850,myocardial remodelling
1851,angiotensin receptor blockers
1852,exposed
1853,criteriabased
1854,p38alpha
1855,allocation
1856,vascular diseases
1857,β-ar drive
1858,coronary artery ligation
1859,left-hand
1860,resynchronization
1861,160 ms
1862,phenylephrine-induced
1863,open-label
1864,postmarketing
1865,proteins
1866,comorbidities
1867,stress echocardiography
1868,hazard ratios
1869,nonselective
1870,acetyl-lysine reader proteins
1871,monocytes
1872,renin-angiotensin-aldosterone
1873,high-volume
1874,doctors
1875,cardiac dysfunction
1876,vehicle-treated
1877,doxorubicin
1878,uncontrolled hypertension
1879,gene
1880,pluripotency marker
1881,angioplasty
1882,vasopressin type 2 receptor antagonist
1883,exercise variables
1884,nitric oxide
1885,congestive
1886,postoperatively
1887,high-strength
1888,nutritional
1889,origin
1890,cc
1891,exercise-induced pulmonary artery systolic pressure
1892,refractory right heart failure
1893,wall stress
1894,interquartile range
1895,chronic disease
1896,doxorubicin-induced cardiotoxicity
1897,deterioration
1898,test-retest
1899,transgenic
1900,mitochondrial ultrastructural
1901,composite end point
1902,predictor
1903,endothelin
1904,heart transplant
1905,p=0.014
1906,signalling pathways
1907,interaction=0.032
1908,myofiber
1909,6-min walk test
1910,adjunctive
1911,lbbb
1912,myoctyes
1913,guideline-recommended
1914,cascades
1915,aimed
1916,economic
1917,guideline
1918,effector molecules
1919,single-arm analysis
1920,heart failure-related
1921,non-lbbb
1922,acute
1923,channel-dependent
1924,systolic blood pressure
1925,precapillary
1926,trichrome
1927,electrolytes
1928,anti-neoplastic agent
1929,defense
1930,lyso-paf-at
1931,bound
1932,tertiary
1933,alendronate
1934,rise
1935,ischemic heart failure
1936,biopsies
1937,acute autonomic nervous system
1938,bridging
1939,type ii regulatory
1940,angiotensin
1941,yield
1942,uncommon
1943,dramatic
1944,composite response
1945,nonadherence
1946,physiological
1947,left ventricular assist devices
1948,wild-type rad
1949,second-generation sulfonylureas
1950,basis
1951,correlations
1952,β-adrenergic receptor blocker
1953,precapillary pulmonary hypertension
1954,estimated glomerular filtration rate
1955,pathophysiological
1956,intervention
1957,anthracycline-related
1958,pb
1959,hospitalized
1960,attendance
1961,functionally
1962,molecular analysis
1963,metoprolol
1964,colon
1965,latter
1966,prospectively
1967,mrnas
1968,cardiac events
1969,avp
1970,myocarditis
1971,heart transplantation
1972,left
1973,ctnt
1974,ventricular action potentials
1975,out
1976,myocardial phosphodiesterase-2
1977,treadmill testing
1978,vascular
1979,resting hr
1980,apoptosis
1981,plasma membrane translocation
1982,wide qrs complex
1983,trial
1984,study-drug
1985,cardiovascular event-free
1986,adenoviral vector
1987,unintentional
1988,sodium
1989,multiple myeloma
1990,peak o2
1991,anesthetized
1992,exertional
1993,inflammation
1994,esmolol
1995,safety monitoring board
1996,morbidity
1997,matched controls
1998,insulin resistance
1999,binding
2000,chf
2001,diffuse
2002,blood urea nitrogen
2003,confidence interval
2004,context
2005,myofiber shortening
2006,murine
2007,lability
2008,indication
2009,caloric
2010,unsuccessful
2011,inhospital
2012,sympathetic tone
2013,fractional shortening
2014,post-myocardial infarction
2015,athletes
2016,moderate-intensity
2017,nurse practitioner
2018,reversed
2019,arm cuff
2020,workload
2021,unfit
2022,design
2023,dithiothreitol
2024,p=0·035
2025,aor
2026,myocardial oxygen consumption
2027,wedge pressure
2028,self-management
2029,reduced ejection fraction
2030,signalosome complex
2031,rest
2032,independent of age
2033,littermate
2034,case-fatality rate
2035,cross-sectional
2036,dipeptidyl peptidase-4
2037,primary outcome
2038,cardiopulmonary resuscitation
2039,left ventricular biopsies
2040,myocardial infarction
2041,adhesion
2042,blunted
2043,energy metabolism
2044,α=0.96
2045,community-based
2046,indeterminable
2047,magnetically
2048,creatinine
2049,coronary
2050,covariate adjustment
2051,bromodomain-containing
2052,prognostic factor
2053,resonance imaging
2054,de novo
2055,progenitors
2056,protein kinase
2057,electromechanics
2058,device-related
2059,socioeconomic
2060,heterochromatic chromatin
2061,c=24.3
2062,chronic thromboembolic pulmonary hypertension
2063,outpatients
2064,cardiac angiogenesis
2065,natriuretic peptides
2066,heart beat
2067,risk of incident
2068,hypertensive heart disease
2069,2+)-pump
2070,interconnected
2071,glomerular filtration rate
2072,mild
2073,hypokalemia
2074,fragmentation
2075,rate variability
2076,hypoalbuminemia
2077,quality-of-life
2078,angiotensin converting enzyme inhibitors
2079,adverse events
2080,functional class iii
2081,left ventricular diastolic end diameter
2082,shift
2083,9-s
2084,midregional proanp
2085,breathing control
2086,pulmonary vascular resistance
2087,ventricular dysfunction
2088,heterogeneity
2089,intensity
2090,uptitration
2091,neurohumoral blockers
2092,carotid bodies
2093,macrophages
2094,washout
2095,walk distance
2096,crt
2097,strategies
2098,tolerated
2099,preserved mitral valve opening
2100,pediatric
2101,linked
2102,afterload
2103,complications
2104,syndrome
2105,effectively
2106,medications
2107,cardiac growth
2108,remodeling
2109,propensity-score matched control
2110,herbal medicine
2111,aric
2112,diastolic tethering
2113,rvpo
2114,2 diabetes
2115,adoption
2116,exercise performance
2117,diagnosis
2118,single-institution
2119,auscultation
2120,nonmitochondrial protein
2121,comorbid
2122,emergency department
2123,administration of contrast agent
2124,alternative
2125,saxagliptin
2126,resistance
2127,followed-up
2128,paradigm
2129,coronary perfusion
2130,recipients
2131,background
2132,consecutive case
2133,sequential
2134,clin
2135,receptors
2136,continuity
2137,renal dysfunction
2138,signaling
2139,atheromatous
2140,angiotensin-converting enzyme inhibitor
2141,restoration
2142,nonsignificant
2143,isoproterenol
2144,nonspecific
2145,4-fold
2146,essential
2147,hf-related
2148,transmitral flow
2149,low-risk
2150,quality
2151,cardiac volume overload
2152,blunts
2153,all-cause medical
2154,cardiovascular event
2155,sphingosine-1-phosphate
2156,retrospective cohort
2157,disturbed intestinal barrier
2158,carotid intima-media
2159,refractory congestive heart failure
2160,safe
2161,ultrastructural
2162,patient-operated electrocardiographic device
2163,end-diastolic pressure
2164,urgent
2165,up
2166,bolus
2167,confidence intervals
2168,diabetes
2169,activation
2170,institution of pd
2171,vasopressin receptor antagonist
2172,interventricular delay
2173,mir-25 expression
2174,left atrium
2175,heart muscle
2176,ser77
2177,composite
2178,p=0.022
2179,downregulation
2180,peak
2181,n=142
2182,restorative
2183,fixed-rate atrial pacing
2184,diabetic
2185,non-aas
2186,randomize
2187,arterial elastance
2188,venous thromboembolic events
2189,improved survival
2190,end-stage congestive heart failure
2191,diastolic mitral annulus velocity
2192,myocardial t1
2193,dilated poorly
2194,choline
2195,left ventricular end-diastolic pressure
2196,antihyperglycemic agents
2197,forty-six
2198,cad
2199,preserved lv ejection fraction
2200,aortic constriction
2201,methods
2202,hospitalizations
2203,chemical
2204,al
2205,published taxonomy
2206,rheumatic fever
2207,beat-to-beat
2208,or diabetes mellitus
2209,open
2210,anthracycline-treated
2211,ventricular mass
2212,early-activated septum
2213,new-user
2214,placebo-treated
2215,disease risk score
2216,univariate
2217,multivariate logistic regression analysis
2218,reduction
2219,laboratory
2220,end-stage hf
2221,insight
2222,condition
2223,downstream signaling
2224,intention-to-treat
2225,fundamental
2226,disease
2227,co-morbidity
2228,dual energy
2229,posteriorly
2230,institution
2231,cardiac stress
2232,cardiac disease
2233,biology
2234,regression analysis
2235,mildly
2236,n=161
2237,parasympathetic tone
2238,bradyarrhythmias
2239,plasma
2240,mitral valve plasty
2241,rotation
2242,secondary end points
2243,technical
2244,exercise-induced
2245,admitted
2246,shaping
2247,turbulence
2248,cardiac sodium
2249,predictors
2250,validated
2251,perfusion
2252,her
2253,intestinal dysfunction
2254,lean mass
2255,beta-blocker
2256,loop diuretics
2257,secondary
2258,i.p.
2259,interventions
2260,allopurinol
2261,migration
2262,readmission
2263,mitral
2264,briefing
2265,psss
2266,acetyltransferases
2267,cardiac resynchronization therapy
2268,kidney infection
2269,re-express
2270,reactivation
2271,mo
2272,β1-adrenergic receptor
2273,circulatory
2274,end-tidal co2
2275,matched cohort study
2276,elderly
2277,robust
2278,embolize
2279,2-erk1 / 2
2280,importance
2281,rnas
2282,6-mwt
2283,channels
2284,low-frequency
2285,density
2286,magnetic resonance spectroscopy
2287,northwest
2288,intracellular
2289,decrement
2290,angiotensin-receptor blockers
2291,ip
2292,endothelial growth factor blockade
2293,communicate
2294,iron homeostasis
2295,10-eo-cfu
2296,metoprolol succinate
2297,trastuzumab
2298,grading
2299,vascular effects
2300,practice settings
2301,sparing
2302,septal wall
2303,cardioverter-defibrillator device
2304,consistently
2305,at rest
2306,annular
2307,offset
2308,continuity equation
2309,morphology
2310,type 2 diabetes
2311,left ventricular dyssynchrony
2312,central end-systolic pressure
2313,adaptive
2314,insurance
2315,neprilysin inhibitor
2316,cultured cardiomyocytes
2317,agonist
2318,btes
2319,left ventricular function
2320,early -
2321,acute myocardial infarction
2322,anxiety
2323,central blood pressure
2324,nicorandil
2325,osteomedullary biopsy
2326,adjuvant
2327,velocity
2328,control adenovirus
2329,effective
2330,outflow
2331,renal function
2332,cardiology
2333,life support
2334,transcatheter
2335,etiology
2336,cardiac function
2337,relaxation
2338,multivariable regression
2339,hospitalisation
2340,6-minute walk test
2341,mitochondrial function
2342,monoclonal
2343,oxidative stress
2344,nmol
2345,two-center
2346,systolic
2347,peripheral arterial disease
2348,assay
2349,crucial
2350,retrieved
2351,cm2
2352,quality of life
2353,length relations
2354,central glycosylated region
2355,deacetylases
2356,orally
2357,inotropes
2358,multivariate model
2359,rr
2360,multiple-procedure
2361,bpm
2362,aortic insufficiency
2363,cutoff
2364,β-blocker
2365,post-transplant
2366,elicited
2367,prescribed
2368,risk-standardized
2369,sampling
2370,stenting
2371,strategy
2372,spironolactone
2373,icd-hf
2374,prone
2375,low-volume institutions
2376,inflammation-stimulated
2377,linear mixed models
2378,intubations
2379,diastolic failure
2380,continuous flow
2381,cv
2382,magnetic resonance
2383,enrollment
2384,collagen deposition
2385,exercise training
2386,post-aac
2387,cardiac hypertrophy
2388,pef
2389,strain
2390,indicator
2391,dual x-ray absorptiometry
2392,aerobic
2393,endothelial cell
2394,right ventricular pump function
2395,death
2396,jehovah 's witness
2397,regression analyses
2398,etiologic
2399,mitral regurgitation
2400,abrogated
2401,cardioprotection
2402,bnp
2403,β1ars
2404,drawn
2405,resonance postcontrast
2406,cardiovascular events
2407,intravenous inotropes
2408,life-sustaining
2409,generator
2410,prolonged
2411,he
2412,resistin
2413,chamber patterning
2414,induced
2415,procedure-related
2416,disorder
2417,kappa coefficient
2418,blood testing
2419,defibrillator-only
2420,function
2421,regression
2422,kinase
2423,implantations
2424,end points
2425,uptake
2426,late-onset
2427,mitochondrial oxidation
2428,social support
2429,end of diastole
2430,atrial pressure
2431,education
2432,transcriptional analysis
2433,maladaptive
2434,multimarker-based
2435,median body mass index
2436,pressure-volume
2437,infarct
2438,hf evolution
2439,hypo-response
2440,responsive
2441,body mass index
2442,secondary outcomes
2443,appendicular lean mass index
2444,dilated lv
2445,postnatal
2446,skinfold thickness
2447,12-lead ecg
2448,physical exertion
2449,2-vessel
2450,resynthesis
2451,odds ratio
2452,age-matched
2453,acute pulmonary embolism
2454,anthracycline-induced cardiotoxicity
2455,shunts
2456,continuous-flow
2457,health
2458,post-hct
2459,resection
2460,right ventricular contractile reserve
2461,diagnostic
2462,valvular
2463,co-morbidities
2464,infarcted
2465,total expenditures
2466,cardiac remodeling
2467,homozygous
2468,physiologic
2469,nursing-sensitive
2470,molecule
2471,abolished
2472,drug
2473,mitral valve
2474,compliance
2475,β-blocker-induced
2476,cardiac injury
2477,non-frail
2478,echo-doppler cardiography
2479,acute coronary syndrome
2480,diastole
2481,deaths
2482,repeated interventions
2483,depressive
2484,bridge to transplantation
2485,high-sensitivity
2486,energy
2487,autonomic nervous system
2488,myocardial dd
2489,deficit index
2490,acf
2491,systolic mitral annulus velocity
2492,eligibility
2493,efficacy
2494,inflow velocity
2495,pump-exchange
2496,428.xx
2497,prescribing
2498,mass spectrometric analysis
2499,right ventricle
2500,shunt
2501,ventricular assist devices
2502,preserved cardiac index
2503,symptomatic systolic heart failure
2504,end-diastolic area
2505,sarcomere
2506,bioprosthetic valve replacement
2507,aforementioned parameters
2508,β2-receptor haplotype
2509,mva
2510,cyclic
2511,epicatechin
2512,pre-hct
2513,echocardiography
2514,ventricular cardiomyocytes
2515,exercise tolerance
2516,chromatin
2517,ras
2518,molecular pathways
2519,structure
2520,cgmp synthesis
2521,beta blockers
2522,cardiac troponin t
2523,3-vessel
2524,translational repression
2525,peripheral vascular disease
2526,endothelial repair
2527,trans
2528,congestive heart failure
2529,guanylate cyclase
2530,bottleneck shape
2531,cellular plasticity
2532,coronary artery disease
2533,septum
2534,positive
2535,power index
2536,defibrillator
2537,vena cava
2538,cellular dysfunction
2539,decile
2540,paced
2541,closure
2542,germline
2543,acute rv decompensation
2544,peak oxygen uptake
2545,adjusted odds ratio
2546,inhibitory
2547,aortic pressure
2548,left ventricular filling pressure
2549,admission
2550,anticoagulants
2551,networks
2552,sulfonylureas
2553,cardiac plasma membrane
2554,left ventricular assist system
2555,ventricular assist device
2556,strength
2557,reflective
2558,waist
2559,hazard models
2560,furosemide
2561,practice-level
2562,end-systolic volume
2563,conscious
2564,tidal respiration
2565,hospitalisations
2566,dissemination
2567,left anterior
2568,pf
2569,rhythm -
2570,implantation
2571,up-regulated
2572,valsartan
2573,combined training
2574,growth
2575,left ventricular longitudinal systolic strain
2576,potential
2577,antitumor activity
2578,etiologies
2579,spectral
2580,adamantly
2581,multivariate models
2582,dyssynchronous nonfailing
2583,p=0.004
2584,β-adrenergic receptor blockade
2585,breast cancer
2586,myocardial fibrosis
2587,stenotic
2588,nonterminal epitopes
2589,time-dependent
2590,loss
2591,mapping
2592,diastolic murmurs
2593,dose-related
2594,right pulmonary artery
2595,algorithms
2596,ckd
2597,calreticulin
2598,exercise
2599,system -
2600,red blood cell transfusion
2601,progressive
2602,multicenter
2603,drugs
2604,insertion
2605,papillary muscles
2606,myocardial extracellular matrix
2607,overexpress
2608,significant
2609,catecholamine
2610,emean
2611,strata
2612,excitation-contraction
2613,hum-retn
2614,cellular metabolism
2615,anemia
2616,histologically
2617,intravenous
2618,left ventricular dysfunction
2619,foundation
2620,case-control
2621,genotyped
2622,health-care
2623,derangement
2624,beats
2625,dyssynchronous hf
2626,myxoma
2627,renin inhibitors
2628,vegetables
2629,microarray
2630,retrospective chart
2631,reciprocal regulation
2632,histologic
2633,mechanical circulatory support
2634,thrombosis
2635,external
2636,mitral valve opening
2637,perspective
2638,hypertrophic
2639,narrow qrs complex
2640,consistent
2641,purpose of review
2642,extra corporeal membrane oxygenation
2643,(-)-epicatechin-rich cocoa
2644,crude
2645,404.x3
2646,chronic decompensated heart failure
2647,β coefficient
2648,randomization
2649,t1-mapping
2650,high-frequency
2651,cardiac explant
2652,compensatory hypertrophy
2653,kidney failure
2654,healthcare
2655,patient
2656,hyperinsulinemia
2657,atypical
2658,peripheral oedema
2659,contextual
2660,instability
2661,cardiovascular disease
2662,strokes
2663,cardiac transplantation
2664,cardiomyopathic
2665,resistive
2666,qt variability
2667,consultation
2668,worldwide
2669,signalling pathway
2670,exercise protocol
2671,refill
2672,stay
2673,cardiologists
2674,anticoagulation
2675,primary
2676,severe hypertension
2677,ventricularly
2678,left ventricular dilatation
2679,6-week
2680,systemic blood pressure
2681,oxidase
2682,β-blockade
2683,pacing-induced chf
2684,tumors
2685,derivation
2686,coagulability
2687,adaptation
2688,lad
2689,died
2690,cardiopulmonary exercise
2691,left ventricular tissue
2692,functions
2693,3.5-fold
2694,medicine
2695,pulmonary capillary wedge pressure
2696,electric
2697,subsequent events
2698,functional status
2699,mitochondrial dysfunction
2700,trials-enriching patient
2701,conditional
2702,safety
2703,nbdmard
2704,warranted
2705,lactate
2706,hypothesized
2707,subproteome
2708,outweigh
2709,functional
2710,left atrial pressure
2711,atrial area
2712,right ventricular fractional area
2713,hretn
2714,advanced hf
2715,hgb
2716,descending
2717,tachypacing-induced
2718,mg·kg(-1)·day(-1)
2719,acetylcholinesterase inhibition
2720,physical examination
2721,subpulmonary ventricle
2722,human-to-human contact
2723,contrast agent
2724,tolvaptan
2725,fluorescence resonance energy
2726,unfamiliar
2727,time interval
2728,anaerobic threshold
2729,monomeric
2730,multihospital
2731,non-ischemic
2732,t test
2733,abstract
2734,norepinephrine-induced
2735,raloxifene-treated
2736,e'lateral
2737,snared
2738,coronary artery bypass grafting
2739,symptom
2740,implantable cardioverter defibrillator-crt
2741,heart failure.
2742,alendronate-
2743,cohort study
2744,fixed
2745,proof-of-principle
2746,protective mechanisms
2747,implantable defibrillators
2748,composite hf index
2749,endpoint
2750,met
2751,nephropathy
2752,r=-0.11
2753,with.estimates
2754,clear
2755,volunteers--a
2756,cardiac failure
2757,hypothesis
2758,two-vessel disease
2759,across-the-board
2760,retrospective descriptive research
2761,sphingosine-1-phosphate receptor
2762,halts
2763,all-cause hospitalization
2764,unanchors
2765,nephrectomy
2766,society
2767,hyperkalemia
2768,vital
2769,primary endpoint
2770,chemotherapy
2771,complication
2772,time-limited
2773,lean
2774,myxomas
2775,extreme
2776,relative minimal detectable change
2777,antitachycardia pacing
2778,fractal
2779,insulin-stimulated
2780,adherence
2781,anabolic
2782,immunoassays
2783,overstimulation
2784,nondiabetes
2785,absorptiometry
2786,iron deficiency
2787,myocyte diameter
2788,n=100
2789,atrial fibrillation
2790,circumflex artery
2791,subproteomes
2792,ion channelopathies
2793,hearts
2794,value=0.027
2795,unclear
2796,operative
2797,peak ca
2798,ablation
2799,decision-support
2800,intermuscular fat ratio
2801,cardiomyocyte bioenergetics
2802,transplantations
2803,upstream signal
2804,key
2805,gender-matched
2806,hypertensive
2807,injected
2808,protein-c
2809,mrna
2810,holosystolic murmur
2811,valve
2812,endothelial function
2813,heart failure
2814,base
2815,myocardial diastolic dysfunction
2816,ans
2817,technique
2818,occluded
2819,natriuretic peptide
2820,radiation
2821,periodic breathing
2822,low-dose
2823,discharges
2824,biomedical
2825,fatigue
2826,mitochondrial energy production
2827,stress
2828,extracellular matrix
2829,physicians
2830,slope
2831,gradient
2832,therapy
2833,surgery
2834,exercise test
2835,canadian
2836,strain rate
2837,long-acting
2838,multivariable analysis
2839,posterior wall infarction
2840,antagonists
2841,outline
2842,basal rotations
2843,in-hospital
2844,pulmonary embolism
2845,degenerative mitral valve
2846,free wall
2847,right ventricular ejection fraction
2848,management
2849,deranged
2850,prevalent
2851,end-stage heart failure
2852,post-translational
2853,pathobiology
2854,net
2855,outpatient
2856,office-based
2857,adipose tissue
2858,relative risk
2859,systolic dysfunction
2860,sitagliptin
2861,aerobic exercise training
2862,proteolysis
2863,hemoglobin
2864,collinearity
2865,guideline-directed medical therapy
2866,hazard analyses
2867,1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase
2868,annular velocity
2869,overexpression
2870,whites
2871,efficiency
2872,transduction pathways
2873,symptomatic
2874,2-erk1
2875,titin
2876,transient
2877,discharged
2878,enrolled
2879,chronic hf
2880,cutoff point
2881,left ventricle end-diastolic pressure
2882,hf-induced
2883,latin america
2884,ischemic mitral regurgitation
2885,hypophosphorylation
2886,t2
2887,mechanical
2888,circulation
2889,nesiritide
2890,tac-induced
2891,arrhythmias
2892,leaflet
2893,body composition
